- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
AbbVie, Disco Pharma Strike USD 2.54 Billion Cancer Drug Development Deal

London: AbbVie agreed to pay up to USD 2.54 billion to develop cancer treatments with Disco Pharmaceuticals, the Germany-based private biotech said on Thursday, marking an early-stage push by the drugmaker on next-generation bispecific therapies.
Bispecific antibodies, a class of cancer medicines that bind two targets at once, have drawn increased interest from big drugmakers including Bristol Myers Squibb, Pfizer and Merck.
In January, AbbVie paid RemeGen $650 million upfront for rights outside China to a bispecific medicine targeting solid tumors.
Disco will receive $40 million upfront and up to $2.5 billion in milestone payments as part of the deal to develop so-called AND-gated bispecific therapeutics for solid tumors. It will also be eligible for tiered royalties on worldwide net sales.
The approach is designed to recognize cancer cells only when two target proteins are present simultaneously, potentially reducing damage to healthy tissue.
Disco CEO Mark Manfredi said his company will be responsible for the research and discovery. AbbVie will have the right to exclusively license selected programs for further development.
"(AbbVie) brings a wealth of information, a wealth of experience in target biology, so we will learn from them and we will work with them on how to select targets," said Manfredi.
The deal is at a very early stage. Disco did not disclose how many programs could be covered or when any could enter clinical development, and AbbVie's license option applies only after Disco completes specified research.
Disco has been developing AND-gated therapies for small-cell lung and colorectal cancer, and Manfredi said the company will select a development candidate in the second half of next year.
Other recent bispecific deals include Bristol Myers Squibb's up to $11.1 billion partnership with BioNTech, Takeda's multibillion-dollar deal with China's Innovent and UCB's $2.2 billion acquisition of Candid Therapeutics.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

